JP2023550094A5 - - Google Patents

Info

Publication number
JP2023550094A5
JP2023550094A5 JP2023529970A JP2023529970A JP2023550094A5 JP 2023550094 A5 JP2023550094 A5 JP 2023550094A5 JP 2023529970 A JP2023529970 A JP 2023529970A JP 2023529970 A JP2023529970 A JP 2023529970A JP 2023550094 A5 JP2023550094 A5 JP 2023550094A5
Authority
JP
Japan
Prior art keywords
hla
peptide
optionally
mhc
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023529970A
Other languages
English (en)
Japanese (ja)
Other versions
JP7895943B2 (ja
JP2023550094A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/059050 external-priority patent/WO2022104002A2/en
Publication of JP2023550094A publication Critical patent/JP2023550094A/ja
Publication of JP2023550094A5 publication Critical patent/JP2023550094A5/ja
Application granted granted Critical
Publication of JP7895943B2 publication Critical patent/JP7895943B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023529970A 2020-11-12 2021-11-12 Sars-cov-2免疫優性ペプチドの構築物及びその使用 Active JP7895943B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113024P 2020-11-12 2020-11-12
US63/113,024 2020-11-12
PCT/US2021/059050 WO2022104002A2 (en) 2020-11-12 2021-11-12 Sars-cov-2 immunodominant peptide constructs and uses thereof

Publications (3)

Publication Number Publication Date
JP2023550094A JP2023550094A (ja) 2023-11-30
JP2023550094A5 true JP2023550094A5 (cg-RX-API-DMAC7.html) 2025-07-22
JP7895943B2 JP7895943B2 (ja) 2026-07-28

Family

ID=81601698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023529970A Active JP7895943B2 (ja) 2020-11-12 2021-11-12 Sars-cov-2免疫優性ペプチドの構築物及びその使用

Country Status (7)

Country Link
US (1) US20230398205A1 (cg-RX-API-DMAC7.html)
EP (1) EP4244630A4 (cg-RX-API-DMAC7.html)
JP (1) JP7895943B2 (cg-RX-API-DMAC7.html)
AR (1) AR124054A1 (cg-RX-API-DMAC7.html)
AU (3) AU2021323389B1 (cg-RX-API-DMAC7.html)
TW (1) TW202237626A (cg-RX-API-DMAC7.html)
WO (1) WO2022104002A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115785231A (zh) * 2021-09-10 2023-03-14 广东菲鹏生物有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法
CN120302989A (zh) * 2022-10-05 2025-07-11 帝斯肯医疗公司 Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
AU2023241306B2 (en) * 2022-10-05 2024-10-03 Tscan Therapeutics, Inc. Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1571909A4 (en) * 2002-10-03 2009-11-11 Idm Pharma Inc OPTIMIZED MULTIPOPOP CONSTRUCTS AND USES THEREOF
US20060257852A1 (en) * 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
CA2523875A1 (en) * 2003-04-28 2004-11-11 Public Health Agency Of Canada Sars virus nucleotide and amino acid sequences and uses thereof
WO2004110349A2 (en) * 2003-05-14 2004-12-23 Siga Technologies, Inc. Sars t cell epitopes and methods for identifying same
US11608363B2 (en) * 2018-07-03 2023-03-21 Leidos, Inc Materials and methods for cell-free expression of vaccine epitope concatemers
BR112021023348A2 (pt) * 2019-05-21 2022-02-01 Esperovax Inc Vacinação oral à base de levedura
CA3143533A1 (en) * 2019-08-01 2021-02-04 Madhavan Nallani A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersome
HUE058338T2 (hu) * 2020-02-20 2022-07-28 Euroimmun Medizinische Labordiagnostika Ag Eljárás és reagensek SARS-COV-2 diagnózisára
TW202200199A (zh) * 2020-03-20 2022-01-01 美商百歐恩泰美國公司 冠狀病毒疫苗及使用方法
IT202000006754A1 (it) * 2020-03-31 2021-10-01 Diasorin S P A Saggi per la rivelazione di SARS-CoV-2
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
CN118490818A (zh) * 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
MX2022013945A (es) * 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
CA3178115A1 (en) * 2020-05-19 2021-11-25 Roman YELENSKY Sars-cov-2 vaccines
CN111647054B (zh) * 2020-06-12 2021-12-03 上海祥耀生物科技有限责任公司 一种用于检测新型冠状病毒SARS-CoV-2抗体的试剂及其应用
CA3187028A1 (en) * 2020-06-17 2021-12-23 Tscan Therapeutics, Inc. Sars-cov-2 immunodominant peptides and uses thereof
EP4208193A4 (en) * 2020-09-01 2024-09-25 Helmholtz-Zentrum für Infektionsforschung GmbH MULTI-REGION VACCINES AND IMMUNOGENIC COMPOSITIONS, THEIR PRODUCTION METHODS AND THEIR USES

Similar Documents

Publication Publication Date Title
US20210017599A1 (en) Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
JP6192537B2 (ja) T細胞の標的抗原の同定
Romero et al. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
US20050130117A1 (en) Modulators of lymphocyte activation and migration
JP6718450B2 (ja) キメラ抗原受容体及びその使用方法
US7678379B2 (en) Mycobacterium tuberculosis epitopes and methods of use thereof
CN114019156A (zh) 免疫突触的质量预测了嵌合抗原受体(car)t细胞的效能
JP2024546018A5 (cg-RX-API-DMAC7.html)
JP2007536522A (ja) Ctlの媒介による抗原提示細胞の溶解を検出するためのmhc架橋系
US7521192B2 (en) EDG: modulators of lymphocyte activation and migration
Hill et al. Early‐onset myasthenia gravis: A recurring T‐cell epitope in the adult‐specific acetylcholine receptor ε subunit presented by the susceptibility allele HLA‐DR52a
AR124054A1 (es) CONSTRUCCIONES DE PÉPTIDOS INMUNODOMINANTES DE SARS-CoV-2 Y SUS USOS
JP2024515646A5 (cg-RX-API-DMAC7.html)
JP5999703B2 (ja) HLA−DR1拘束性Tax特異的CD4+T細胞エピトープ
EP4378533A1 (en) Patient selection and therapy monitoring for autoimmune disorders
Asano et al. Tumor regression following engineered polyomavirus-specific T cell therapy in immune checkpoint inhibitor-refractory merkel cell carcinoma
US20130189282A1 (en) Methods for isolating and using a subset of cd8 t-cells that are resistant to cyclosporin
ES3041245T3 (en) Methods for detecting a mycobacterium tuberculosis infection
Levin et al. Availability of autoantigenic epitopes controls phenotype, severity, and penetrance in TCR Tg autoimmune gastritis
US20030013107A1 (en) Alpha 2 integrin: modulators of lymphocyte activation
IL310374A (en) Antigen binding proteins that uniquely bind CT45
WO2011040978A2 (en) Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
US20020146747A1 (en) TRAC1: modulators of lymphocyte activation
EISEN et al. VIII. Altered Peptide Ligands: Partial Agonists and Antagonists............... 4 1 IX. MHC Restriction by Self and Nonself MHC: The Paradox of Alloaggression. 43
US20050250113A1 (en) Mammalian magnesium/manganese sensing G protein coupled receptor